Zynnon AG

Zynnon is on a mission to transform respiratory infection diagnostics by identifying the type of pathogen involved, all through noninvasive bedside monitoring. Our solution provides a state-of-the-art bedside patient monitoring using AI and gas biomarkers detection. It answers an urgent need to reduce the number of Hospitals Acquired Infections (HAI), as well as the misuse and overuse of antibiotics addressing the challenge of Antimicrobial Resistance (AMR). Our sensor device placed at bedside, associated to our AI driven cloud platform, enables clinicians, only when necessary, to deliver the right antibiotic in due time to the patients. Strong partnerships are in place with CSEM and Institut Pasteur, which has led to the grant of Innosuisse funding.